PBI57 Effectiveness of Biologic Treatments for Psoriatic Arthritis in Italy: Preliminary Results of the Chronos Study

Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy characterized by musculoskeletal signs/symptoms, joint pain and tenderness. A wide variety of pharmacologic treatments are available (nonsteroidal anti-inflammatories, corticosteroids, disease-modifying antirheumatic drugs including biologics). Scanty are the evidences of the efficacy of PsA treatments in the real-world. Results of an interim analysis of the Effectiveness of biologic treatments for psoriatic arthritis in Italy: an observational longitudinal study of real-life clinical practice (CHRONOS) study are here presented about 6-month response to biologics. Final results will be available by the end of Sept-2020. CHRONOS is an observational retrospective and prospective cohort study; 410 PsA-diagnosed Italian adults starting a biologic between 6 and 24 months before enrolment were included. Primary objective was to assess the 6-month and 1-year response to biologics according to DAS28-EULAR criteria1. ACR20-50-70 responses and Health Assessment Questionnaire Disability Index (HAQ-DI) were evaluated too. Among 262 patients analysed, 147 (56.1%) were women, mean (SD) age and time from PsA diagnosis were 52.3 (11.8) and 8.2 (7.5) yrs respectively. Naïve to biologics were 127 (48.5%). During observation period (mean (SD): 15.7 (6.2) months) 223 (85.1%) and 32 (12.2%) patients assumed 1 and 2 subsequent biologics, respectively. Considering 174 patients with available DAS28-EULAR 6-month response, the most frequently administered biologics were secukinumab (65, 37.4%), adalimumab/biosimilar (30, 17.2%), etanercept/biosimilar (28, 16.1%) and certolizumab (21, 12.1%) and the 6-month response was good and moderate in 84 (48.3%) and 35 (20.1%) patients, respectively, while 55 (31.6%) patients were non-responders. ACR20, ACR50 and ACR70 6-month response, evaluated on 128 patients, was 45.3%, 31.3% and 18.8%, respectively. Mean (SD) HAQ-DI at therapy start was 1.01 (0.64) and 0.76 (0.63) after 6 months. CHRONOS study preliminary results show a good 6-month DAS28-EULAR response to biologics in 48.3% of PsA patients in real-life setting. 1CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2005. S-93- S-99.